Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genotype 1 or 2 HCV infection~* Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical history or liver biopsy~* Previously treated with a DAA-containing regimen of at least 4 week duration~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL FDC + RBV 12 weeks (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
- SOF/VEL FDC + RBV 24 weeks (Type: EXPERIMENTAL): SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection

Based on this trial design, predict the completion outcome and termination type (if applicable).